ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00640250
Recruitment Status : Completed
First Posted : March 21, 2008
Results First Posted : April 9, 2018
Last Update Posted : April 9, 2018
Sponsor:
Information provided by (Responsible Party):
Allerderm

Brief Summary:
We propose a prospective, multi-center, double-blind, randomized study comparing the diagnostic performance (primary) and safety (secondary) of 3 concentrations of Disperse blue 106 and 4 concentrations of Bronopol in 40 adult subjects (20 subjects per allergen) with a clinical history of contact dermatitis and a positive patch test (current or previous) to the corresponding reference petrolatum allergen ("sensitives").

Condition or disease Intervention/treatment Phase
Contact Dermatitis Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens Phase 2

Detailed Description:

Primary endpoint:

To evaluate the diagnostic performance of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:

  • Determination of the lowest concentration eliciting positive skin reactions (+1 or +2) in 70-90% of sensitive subjects.
  • Frequency of positive, negative, doubtful and irritant reactions for each allergen and tested concentration.
  • Concordance/discordance as compared to the corresponding reference petrolatum allergen.

Secondary endpoint:

To evaluate the safety of Disperse blue 106 and Bronopol T.R.U.E. Test allergens in 20 adult subjects per allergen with a clinical history of contact dermatitis and a positive patch test to the respective reference allergen. Evaluations will include:

  • The frequency of tape-induced irritation at the test site, incomplete panel adhesion, and subject-reported sensations of itching or burning.
  • The frequency and characterization of adverse events and serious adverse events.
  • The frequency and characterization of late and/or persistent reactions.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study
Study Start Date : April 2008
Actual Primary Completion Date : March 2009
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Bronopol
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Sensitives
Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
Biological: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens

Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2

Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.

Other Name: T.R.U.E. TEST® Skin Patch Test: Panel 3.2



Primary Outcome Measures :
  1. Diagnostic Performance: Optimal Test Allergen Concentration [ Time Frame: Visits 3-5: 3-21 days after application ]
    Lowest concentration eliciting 1+ or 2+ positive reactions in 70-90% of subjects

  2. Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration [ Time Frame: Visit 3: 3 days after application ]
    Percentage (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 3- all subjects

  3. Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration [ Time Frame: Visit 4: 7 days after application ]
    Percent (including confidence intervals) of subjects who elicited positive, negative, doubtful and irritant reactions to disperse blue at visit 4- all subjects

  4. Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration [ Time Frame: Visit 3: 3 days after application ]
    Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 3- all subjects

  5. Frequency of Positive, Negative, Doubtful and Irritant Reactions for Each Allergen and Concentration [ Time Frame: Visit 4: 7 days after application ]
    Percentage (including confidence intervals) of subjects who exhibited positive, negative, doubtful and irritant reactions to bronopol at visit 4- all subjects

  6. Concordance Between Investigational Allergen and Reference Allergen [ Time Frame: Visit 5: 21 days after patch application ]
    Concordance between disperse blue or bronopol and the respective reference petrolatum allergen


Secondary Outcome Measures :
  1. Frequency of Irritation (Tape Reactions), Late/Persistent Reactions and Subject-reported Itching or Burning [ Time Frame: Day 2-21 ]

    Percentage of subjects who exhibited irritation and itching or burning at patch removal (entire panel is evaluated) and late/persistent reactions.

    Late reactions occur 7-10 days after patch application Persistent reactions initially occur at 2-4 days after application and persist through 7-21 days after application


  2. Adverse Events [ Time Frame: Days 0-21 ]
    The adverse event-reporting period began at application and ended with the Day 21 visit. Adverse events were followed until they resolved. Serious adverse events and those assessed by the investigator as possibly related to the investigational product were to be followed until they resolved or until the investigator assessed them as chronic or stable.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Current or previous symptoms and/or history consistent with allergic contact dermatitis, and positive patch test (within the past 5 years) to Bronopol OR Current or previous symptoms and/or history consistent with allergic contact dermatitis, and a positive patch test (within the past 5 years) to Disperse blue 106 or Disperse blue 106/124 allergen mix.
  • All subjects must be adults (18 years of age or older) and otherwise in good health.
  • Premenopausal female subjects must consent to a urine pregnancy test; results must be negative for study inclusion.
  • Informed consent must be signed and understood by each subject, and consistent with all institutional, local and national regulations.

Exclusion Criteria:

  • Subjects unable to meet inclusion requirements.
  • Women who are breastfeeding or pregnant.
  • Topical treatment during the last 7 days with corticosteroids or other immunosuppressive agents on or near the test area.
  • Systemic treatment during the last 7 days with corticosteroids (equivalent to > 10 mg prednisone) or other immunosuppressive agents.
  • Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks.
  • Acute dermatitis outbreak or dermatitis on or near the test area on the back.
  • Subjects unable to comply with patch test study requirements including multiple return visits and activity restrictions (e.g., protecting test panels from excess moisture due to showering or vigorous activity).
  • Subject participation in clinical trials of investigational drugs, treatments or devices other than T.R.U.E. Test during this study or 3 weeks prior to inclusion in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00640250


Locations
United States, Kentucky
Dermatology Specialists PSC
Louisville, Kentucky, United States, 40202-1864
Denmark
Odense University Hospital
Odense C, Denmark, DK-5000
Sponsors and Collaborators
Allerderm
Investigators
Principal Investigator: Evy Paulsen, M.D., Ph.D Odense University Hospital
Principal Investigator: Joseph Fowler, MD Dermatology Specialists PSC

Responsible Party: Allerderm
ClinicalTrials.gov Identifier: NCT00640250     History of Changes
Other Study ID Numbers: Mekos 07 2P3.2 201
2007-007130-19 ( EudraCT Number )
WIRB Pr. No.: 20072233 ( Other Identifier: Western Institutional Review Board )
First Posted: March 21, 2008    Key Record Dates
Results First Posted: April 9, 2018
Last Update Posted: April 9, 2018
Last Verified: April 2018

Keywords provided by Allerderm:
Dermatitis, Contact, Bronopol, Disperse Blue 106

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Contact
Skin Diseases
Skin Diseases, Eczematous
Bronopol
Anti-Infective Agents
Anti-Infective Agents, Local